Evaluation of the indirect hemagglutination assay for diagnosis of acute leptospirosis in Hawaii.
Timely diagnosis of leptospirosis is important to ensure a favorable clinical outcome. The definitive serologic assay, the microscopic agglutination test (MAT), requires paired sera and is not useful for guiding early clinical management. The only screening test approved for use in the United States, the indirect hemagglutination assay (IHA), has not undergone extensive field evaluation. To assess the performance of the leptospirosis IHA in Hawaii, serum from patients evaluated for leptospirosis between 1992 and 1997 were tested with the IHA at the Hawaii State Laboratories Division and with the MAT at the Centers for Disease Control and Prevention. Leptospirosis was considered confirmed by a fourfold rise in MAT titer and/or a positive culture. A total of 92 (41%) of 226 specimens from 114 persons with confirmed leptospirosis were found positive by IHA. Only 18 (15%) of 119 specimens obtained within 14 days of onset were IHA positive, compared to 74 (69%) of 107 specimens collected more than 14 days after onset (P <0.001). Repeat testing ultimately resulted in 78 (68%) of the confirmed cases having at least one specimen found positive by IHA. Thirteen different presumptive infecting serogroups were identified among 251 specimens with an MAT titer of >/=200 and obtained from persons with confirmed or probable leptospirosis. Fifty (68%) of 73 specimens with Icterohaemorrhagiae as the presumptive infecting serogroup were found positive by IHA, compared to 44 (47%) of 93 specimens with Australis as the presumptive infecting serogroup (P, 0.01). The IHA test was positive for 3 (1%) of 236 specimens from 154 persons without leptospirosis. The sensitivity of the leptospirosis IHA in Hawaii was substantially below figures reported previously, particularly early in the course of illness, limiting its usefulness for diagnosing acute infection. Since the presumptive infecting serogroup affected IHA results and the prevalence of serovars varies with geography, the performance of the IHA should be assessed locally. More sensitive leptospirosis screening tests are needed in Hawaii.
Effler
P V
PV
Epidemiology Branch, Communicable Disease Division, Hawaii State Department of Health, Honolulu, Hawaii 96813, USA. pveffler@mail.health.state.hi.us
Domen
H Y
HY
Bragg
S L
SL
Aye
T
T
Sasaki
D M
DM
D000208:Acute Disease; D000942:Antigens, Bacterial / Q000097:blood; D006254:Hawaii; D006386:Hemagglutination Tests / Q000379:methods*; D006801:Humans; D007919:Leptospira / Q000302:isolation & purification; D007922:Leptospirosis / Q000097:blood / Q000175:diagnosis*; D008403:Mass Screening / Q000379:methods; D015203:Reproducibility of Results; D012703:Serotyping
D000942:Antigens, Bacterial